Fluoride-labeled Boronophenylalanine PET Imaging in Patients With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor
and investigators. Listing a study does not mean it has been evaluated by the U.S.
Federal Government. Know the risks and potential benefits of clinical studies and talk
to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05538676

Recruitment Status  : Not yet recruiting

First Posted  : September 14, 2022
Last Update Posted  : October 20, 2022

See Contacts and Locations

View this study on Beta.ClinicalTrials.gov

Sponsor:
Tongji Hospital

Information provided by (Responsible Party):

Tongji Hospital

Study Details Tabular View No Results Posted Disclaimer How to Read a Study Record

Study Description Go to 

Brief Summary:
Recently, new high-dose radiation therapy [e.g., boron neutron capture therapy (BNCT)] absorbed into the tumor
tissue has been applied to treat patients with solid tumors. Here we examine and describe how to evaluate the
biological activity of tumors using positron emission tomography (PET) with fluoride-labeled boronophenylalanine (F-
BPA) as a tracer.

Condition or disease  Intervention/treatment 